WSJ reviews Thync mood wearable; GE touts Vizamyl early dementia data;

@FierceMedDev: ICYMI yesterday: Implanting a titanium tube inside damaged bones improves procedure to ward off amputations. Story | Follow @FierceMedDev

@EmilyWFierce: A U.K. research firm is developing tech to make diagnostic tests with an inkjet printer. More from the BBJ | Follow @EmilyWFierce

> The Wall Street Journal offers a favorable review for the mood-shifting wearable Thync device, which launched in June and is backed by Khosla Ventures. More

> GE Healthcare ($GE) offered positive data for its controversial Vizamyl PET amyloid imaging agent that showed it improved diagnosis of early dementia patients. More

> Biotronik has gained FDA nod for its cardiac resynchronization defibrillator Itrevia HF-T QP used with IS4 compatible left ventricular (LV) leads. More

Biotech News

@FierceBiotech: ICYMI: 'Cures' bill, designed to speed drug approvals, could be too much of a good thing, dissenters say. Story | Follow @FierceBiotech

@JohnCFierce: Schoenebaum sees great stuff in $BIIB data, predicts a rise in share price. | Follow @JohnCFierce

@DamianFierce: $BIIB investigator declined to color in 54-week 6mg data with my pen but agreed there should be a lottery. Image | Follow @DamianFierce

> AstraZeneca's once-lauded drug flunks a Phase III eye cancer trial. More

> Xoma crushed as lead drug flunks a PhIII challenge. Article

> In a setback, Biogen's mid-range dose of aducanumab flops in Alzheimer's study. Story

> Roche brings an Alzheimer's drug back from the brink with another PhIII endeavor. News

> Eli Lilly offers evidence of twice-failed solanezumab's impact on Alzheimer's. Report

Pharma News

@FiercePharma: Biosimilars will cut top 10 vulnerable biologics almost in half by 2020: Morningstar. FiercePharmaMarketing report | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Horizon hikes Depomed offer to $2B in bid for 'friendly' deal talks. Report | Follow @CarlyHFierce

> Drugmakers like Gilead, Mylan and Novo, not Big Pharma, are job creators. More

> Should J&J break up? Get ready for a new round of debate. Story

Biotech Research News

> Meta-analysis: Avandia's impact on Parkinson's should spur new research. Report

> Animal study highlights role of mast cells in chronic eye diseases. More

> Specialized cells in Alzheimer's could be used for diagnosis, drugs. Report

> Yale scientists highlight a promising eczema study for Pfizer's Xeljanz. Story

> NYU Langone team spotlights new antibodies for Alzheimer's, Parkinson's. Article

Diagnostics News

> Illumina launches new lab service for HiSeq X sequencing systems. More

> Alere revs up engine with new deals and win for quick strep test. Story

> Exact Sciences reveals $179M public offering amid slumping Q2 sales. News

> Oxford Nanopore reels in $109M to ramp up R&D. Item

> Theranos inks Medicaid deal and snags CLIA waiver to expand Dx reach. Article

Pharma Marketing News

> Will Genzyme's Fabry pill only steal sales from Fabrazyme? Not if it acts like Cerdelga. More

> Abbott boosts generic drug sales by 31% in strong Q2 showing. Item

> Sanofi Pasteur drafts Bollywood star to talk up flu shots in India. Report

> What's in a pill color? Consumers see messages in red, blue, green and white. Story

> The PCSK9 countdown: Amgen's Repatha wins EU race, with Sanofi's Praluent up Friday at FDA. Article